Clinical trial
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood…
NCT00462332 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00462332 |
|---|---|
| Title | Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia |
| Official title | Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features |
| Acronym | LLC0405 |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Fludarabine, Campath, Transplant |
| Enrollment | 86 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Apr 19, 2007 |
| Last update posted | Sep 6, 2013 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: